Therefore, based on our results, ATAD2 inhibitors, combined with CENPE inhibitors or other immunotherapeutic drugs, such as pembrolizumab, should be explored as potentially effective ovarian cancer therapies in patients with advanced or metastatic disease who continue to lack effective and durable therapeutic options. Here, ATAD2 is linked to metastatic neoplasm.